Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Udvidelsesundersøgelse for at evaluere, hvor sikker og tolerabel NBI-921352 er som en supplerende terapi for forsøgspersoner med SCN8A-DEE

10. november 2026 opdateret af: Neurocrine Biosciences

En prospektiv, langsigtet, interventionel, aktiv forlængelsesundersøgelse til evaluering af sikkerheden og tolerabiliteten af ​​NBI-921352 som supplerende terapi hos personer med SCN8A udviklingsmæssigt og epileptisk encefalopatisyndrom (SCN8A-DEE)

Extension study to evaluate how safe and tolerable the drug NBI-921352 is when used as adjunctive therapy in participants with SCN8A developmental and epileptic encephalopathy syndrome (SCN8A-DEE).

Studieoversigt

Status

Afsluttet

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

8

Fase

  • Fase 2

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • California
      • San Francisco, California, Forenede Stater, 94143
        • UCSF Medical Center
    • District of Columbia
      • Washington D.C., District of Columbia, Forenede Stater, 20010
        • Children's National Hospital
    • New York
      • Rochester, New York, Forenede Stater, 14642
        • University of Rochester
    • Texas
      • Fort Worth, Texas, Forenede Stater, 76104
        • Cook Children's Medical Center

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

2 år til 22 år (Barn, Voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Key Inclusion Criteria:

For Participants Who Participated in NBI-921352-DEE2012:

  • Written or oral pediatric assent from the participant and written informed consent from the participant's parent(s) or legal guardian(s) for pediatric participants and adult participants who are not capable of providing consent. Adult participant who are ≥18 years of age and capable of providing consent should sign an Informed Consent Form (ICF).
  • Completed 16 weeks of treatment in Study NBI-921352-DEE2012.
  • Continue to use a nocturnal alerting system or practice consistent with standards of care for the duration of the study.
  • Have an adequate rescue medication regimen per the investigator's judgment in place for the duration of the study.

For Participants Who did not Participate in NBI-921352-DEE2012:

  • Written or oral pediatric assent from the participant if deemed capable of providing assent and written informed consent from the participant's parent(s) or legal guardian(s) for pediatric participants and for adult participants who are not capable of providing consent. Adult participants who are capable of providing consent should sign an ICF.
  • Be a male or female 2 to 21 years of age, inclusive.
  • Have a diagnosis of SCN8A-DEE supported by both clinical and genetic findings.
  • Have on average at least 1 countable motor seizure per week and not be seizure-free for more than 20 consecutive days.
  • Being treated with at least 1 other antiseizure medication (ASM), but no more than 4 ASMs.
  • Have failed to achieve seizure freedom with at least 2 ASMs.
  • Have a body weight of at least 10 kilograms.

Key Exclusion Criteria

For Participants Who Participated in NBI-921352-DEE2012:

- Have developed any other disorder for which the treatment takes priority over treatment of SCN8A-DEE or is likely to interfere with study treatment or impair treatment compliance.

For Participants Who did not Participate in NBI-921352-DEE2012:

  • Have symptoms that would be more consistent with another epilepsy disorder such as Dravet syndrome (for example, fever-induced episodes of status epilepticus, frequent myoclonic seizures, worsening on sodium channel blockers, absence seizures with generalized spike-and-wave electroencephalogram [EEG] as the sole seizure type).
  • Currently receiving cannabinoids or medical marijuana except Epidiolex/Epidyolex, unless approved by the Sponsor.
  • Currently taking systemic steroids (excluding inhaled medication for asthma treatments and intranasal steroids for allergies) such as adrenocorticotropin hormone, high-dose prednisolone for epileptic spasms. If participant has received these medications in the past, they must be off these medications for at least 3 months prior to the screening visit and these drugs may not be initiated during the duration of the study. Intermittent steroids to treat non-epilepsy-related diseases (such as allergies or dermatological conditions) are not exclusionary.
  • Have a history of moderate or severe head trauma or other neurological disorders or systemic medical diseases that are, in the investigator's opinion, likely to affect nervous system functioning.
  • Have a clinically significant medical condition or chronic disease, that in the opinion of the investigator would preclude the participant from participating in and completing the study or that could confound interpretation of study outcome.
  • Have clinically significant abnormal vital signs at the screening visit, as determined by the investigator.
  • Have one or more clinical laboratory test values outside the reference range, based on blood samples taken at the screening visit, that are of potential risk to the participants safety as determined by the investigator.
  • Have, at the screening visit, an electrocardiogram (ECG) finding of a corrected QT interval using Fridericia's formula (QTcF) > 450 milliseconds (msec) or presence of any significant cardiac abnormality.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: NBI-921352

NBI-921352 administered for up to 164 weeks.

Administered orally

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Tidsramme
Number of Participants with Serious treatment-emergent adverse events (TEAEs), TEAEs Leading to Discontinuation and Fatal TEAEs
Tidsramme: Day 1 to Week 168
Day 1 to Week 168

Sekundære resultatmål

Resultatmål
Tidsramme
Percentage Change from Baseline in 28-day Seizure Frequency for Countable Motor Seizures
Tidsramme: Baseline, up to Week 162
Baseline, up to Week 162

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Studieleder: Clinical Development Lead, Neurocrine Biosciences

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

12. juli 2022

Primær færdiggørelse (Faktiske)

12. november 2025

Studieafslutning (Faktiske)

12. november 2025

Datoer for studieregistrering

Først indsendt

26. januar 2022

Først indsendt, der opfyldte QC-kriterier

26. januar 2022

Først opslået (Faktiske)

7. februar 2022

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

13. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

10. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • NBI-921352-DEE2013
  • 2021-004393-62 (EudraCT nummer)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .